Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report analysing the organ transplant industry.
An Incredible Offering of Search Engine Optimization (SEO) Services Integrated with Customer Relationship Management (CRM) Software to Create an Innovative Digital Marketing Solution (PRWeb Apr 26, 2008) Read the full story at http://ww1.prweb.com/releases/2008/04/prweb891004.htm
On May 5, 2008, the FDA is holding a hearing to discuss approving what Purdue Pharma claims is "a safer formulation" of OxyContin--"legal heroin" according to talk-show host Larry G. Larry Golbom, host of The Prescription Addiction Radio show, will
in which treatment of antiviral-naïve adult chronic hepatitis B patients with BARACLUDE® (entecavir) resulted in greater long-term viral load reduction than adefovir at 96 weeks -- consistent with earlier 12-week results (primary endpoint). (PRWeb Apr 26, 2008) Read the full
Online suppliers of erectile dysfunction medications are being exposed for selling fake versions of Viagra, Kamagra, and other ED drugs. Kamagra supplier www.iLoveKamagra.com offers free tips to help consumers protect themselves from mistakenly purchasing these fake medications. (PRWeb Apr 26,
King Pharmaceuticals and Acura Pharmaceuticals have completed patient enrollment for the pivotal Phase III clinical trial evaluating Acurox tablets for relief of moderate to severe pain.
Ligand Pharmaceuticals has initiated a Phase II study of its small-molecule thrombopoietin mimetic, LGD-4665 for the treatment of idiopathic thrombocytopenic purpura.
Latona Life Sciences has entered into two agreements for the acquisition of patent rights and orphan drug status to a novel late-stage drug, Oralgam, for the treatment of juvenile and adult rheumatoid arthritis.
Antipodean Pharmaceuticals has announced positive results from a Phase II trial of its lead compound MitoQ in liver disease. The trial successfully met the primary clinical endpoint, the reduction of elevated liver enzymes.
Aida Pharmaceuticals has completed the acquisition of a controlling interest in Jiangsu Institute of Microbiology, a microbiology research institute in the People's Republic of China.
Boston Scientific has completed enrollment in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy, known as MADIT-CRT.
Pharmasset has announced that it will enroll two additional cohorts in the on-going Phase I study protocol to evaluate four weeks of combination therapy with R7128.
The Children's Hospital Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq from and after October 1, 2007, to Royalty Pharma for $182 million in cash.
Jerini has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for icatibant in the treatment of acute attacks of hereditary angioedema.
Forbes Medi-Tech has extended its supply and licensing contract with Pharmavite until mid 2009 for the continued sale of Reducol, the branded cholesterol lowering ingredient in one of Pharmavite's dietary supplements, Nature Made CholestOff and CholestOff Complete.
Progenics Pharmaceuticals and Wyeth Pharmaceuticals, a division of Wyeth, have received FDA approval for Relistor subcutaneous injection for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not
Proteus Biomedical has initiated the Retime 2.0 study to assess the performance of the company's cardiac electric tomography and multi-sensor lead system for the measurement of cardiac performance in heart failure patients undergoing implantation of a cardiac resynchronization therapy device.
